Biotech Bulls & Breakthroughs

The FDA is in flux, ESMO is approaching, and a series of clinical and regulatory catalysts could put biotech stocks in focus. John Gagliano and Sheff Sheffield mark their 20th episode together by reviewing developments and the companies on their radar. They discuss: 🔹 FDA leadership shakeup 🔹 ESMO in Madrid and the readouts 🔹 Catalysts to watch before year-end and early 2027. In this episode, you’ll hear about: Aldeyra Therapeutics (ALDX) and the potential relevance of the Outlook The...

In this episode, John Gagliano and Sheff Sheffield discuss the biggest biotech catalysts heading into the final months of 2026. They examine continued big-pharma acquisition activity, Novo Nordisk’s pediatric obesity data, GLP-1 expansion, and the importance of pinpointing dates for clinical readouts, regulatory decisions, and conference presentations. You'll discover: 🔹 Why big pharma M&A could continue supporting small- and mid-cap biotech stocks 🔹 How GLP-1 developments and pedi...

In this episode features John Gagliano in conversation with Stephan Jackman, CEO and director of Alzamend, about the company’s mission, “Making Alzheimer’s just a memory,” and its pipeline in Alzheimer’s and related neuropsychiatric disorders. They cover how Alzamend is trying to improve on current treatments by focusing on safer, more targeted approaches, including a next-generation lithium and an autologous immunotherapeutic vaccine. Alzamend Neuro Inc. https://www.biopharmcatalyst.com/com...

In this episode, John Gagliano and Sheff Sheffield unlock hidden strategies behind biotech success, from FDA decision dynamics to the most promising upcoming catalysts; they reveal how savvy investors spot opportunities before the crowd catches on. If you're tired of missing the moves that matter and want expert insights into the biotech landscape, this episode is your essential guide. You'll discover: 🔹 How to interpret FDA interactions 🔹 The impact of early-stage data releases and cl...

In this episode, John Gagliano and Sheff Sheffield discuss recent developments in biotech, including FDA policy shifts, key catalysts for upcoming biotech stocks, and market trends amidst frothy conditions. Essential insights for investors looking to navigate the biotech landscape in 2026. 🔹 FDA policy shift towards flexible trial requirements 🔹 Impact of one pivotal trial on biotech investment strategies 🔹 Upcoming biotech catalysts and FDA approval dates 🧭 Track upcoming catalysts: https:/...